Avelumab for Advanced Merkel Cell Carcinoma: Global Real-World Data on Patient Response and Survival

References

• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Merkel cell carcinoma; 2023. Available from: https://merkelcell.org/wp-content/uploads/2022/04/NCCN-Guidelines-for-Merkel-Cell-Carcinoma-v1.2023.pdf. Accessed June 25, 2023.
   Google Scholar
• Harvey JA, Mirza SA, Erwin PJ, Chan AW, Murad MH, Brewer JD. Recurrence and mortality rates with different treatment approaches of Merkel cell carcinoma: a systematic review and meta-analysis. Int J Dermatol. 2022;61(6):687–697. doi:10.1111/ijd.15753
   PubMed Web of Science ®Google Scholar
• Cowey CL, Liu FX, Kim R, et al. Real-world clinical outcomes with first-line avelumab in locally advanced/metastatic Merkel cell carcinoma in the USA: SPEAR-Merkel. Future Oncol. 2021;17(18):2339–2350. doi:10.2217/fon-2020-1250
   PubMed Web of Science ®Google Scholar
• Paulson KG, Park SY, Vandeven NA, et al. Merkel cell carcinoma: current US incidence and projected increases based on changing demographics. J Am Acad Dermatol. 2018;78(3):457–463.e2. doi:10.1016/j.jaad.2017.10.028
   PubMed Web of Science ®Google Scholar
• Sergi MC, Lauricella E, Porta C, Tucci M, Cives M. An update on Merkel cell carcinoma. Biochim Biophys Acta Rev Cancer. 2023;1878(3):188880. doi:10.1016/j.bbcan.2023.188880
   PubMed Web of Science ®Google Scholar
• Kieny A, Cribier B, Meyer N, Velten M, Jégu J, Lipsker D. Epidemiology of Merkel cell carcinoma. A population-based study from 1985 to 2013, in northeastern of France. Int J Cancer. 2019;144(4):741–745. doi:10.1002/ijc.31860
   PubMed Web of Science ®Google Scholar
• Youlden DR, Soyer HP, Youl PH, Fritschi L, Baade PD. Incidence and survival for Merkel cell carcinoma in Queensland, Australia, 1993–2010. JAMA Dermatol. 2014;150(8):864–872. doi:10.1001/jamadermatol.2014.124
   PubMed Web of Science ®Google Scholar
• Song PI, Liang H, Wei WQ, Jiang YQ, Smith JS, Qiao YL. The clinical profile of Merkel cell carcinoma in mainland China. Int J Dermatol. 2012;51(9):1054–1059. doi:10.1111/j.1365-4632.2011.05251.x
   PubMed Web of Science ®Google Scholar
• Grignani G, Chiarion Sileni V, Pinto C, et al. Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program. J Transl Med. 2021;19(1):70. doi:10.1186/s12967-021-02730-8
   PubMed Web of Science ®Google Scholar
• Lewis DJ, Sobanko JF, Etzkorn JR, et al. Merkel Cell Carcinoma. Dermatol Clin. 2023;41(1):101–115. doi:10.1016/j.det.2022.07.015
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Orlova K, Grignani G, et al. Avelumab expanded access program in metastatic Merkel cell carcinoma: efficacy and safety findings from patients in Europe and the Middle East. Int J Cancer. 2021;149(11):1926–1934. doi:10.1002/ijc.33746
   PubMed Web of Science ®Google Scholar
• Munhoz RR, Cayol F, Corrales L, et al. Merkel cell carcinoma in Latin America: a contribution from an expanded access program for avelumab to address issues from experts’ recommendations. Cancer Immunol Immunother. 2021;70(4):1031–1036. doi:10.1007/s00262-020-02756-9
   PubMed Web of Science ®Google Scholar
• Averbuch I, Stoff R, Miodovnik M, et al. Avelumab for the treatment of locally advanced or metastatic Merkel cell carcinoma-A multicenter real-world experience in Israel. Cancer Med. 2023;12(11):12065–12070. doi:10.1002/cam4.5890
   PubMed Web of Science ®Google Scholar
• Robertson JP, Liang ES, Martin RC. Epidemiology of Merkel cell carcinoma in New Zealand: a population-based study. Br J Dermatol. 2015;173(3):835–837. doi:10.1111/bjd.13782
   PubMed Web of Science ®Google Scholar
• Aw D, Silva AB, Palmer DB. Immunosenescence: emerging challenges for an ageing population. Immunology. 2007;120(4):435–446. doi:10.1111/j.1365-2567.2007.02555.x
   PubMed Web of Science ®Google Scholar
• Moll R, Löwe A, Laufer J, Franke WW. Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am J Pathol. 1992;140(2):427–447.
   PubMed Web of Science ®Google Scholar
• Rastrelli M, Ferrazzi B, Cavallin F, et al. Prognostic factors in Merkel cell carcinoma: a retrospective single-center study in 90 patients. Cancers (Basel). 2018;10(10):350. doi:10.3390/cancers10100350
   PubMed Web of Science ®Google Scholar
• Tarantola TI, Vallow LA, Halyard MY, et al. Prognostic factors in Merkel cell carcinoma: analysis of 240 cases. J Am Acad Dermatol. 2013;68(3):425–432. doi:10.1016/j.jaad.2012.09.036
   PubMed Web of Science ®Google Scholar
• Paulson KG, Iyer JG, Blom A, et al. Systemic immune suppression predicts diminished Merkel cell carcinoma-specific survival independent of stage. J Invest Dermatol. 2013;133(3):642–646. doi:10.1038/jid.2012.388
   PubMed Web of Science ®Google Scholar
• Wang LL, Lin SK, Stull CM, et al. Cutaneous Oncology in the Immunosuppressed. Dermatol Clin. 2023;41(1):141–162. doi:10.1016/j.det.2022.07.012
   PubMed Web of Science ®Google Scholar
• Levy S, Aarts MJB, Eskens FALM, et al. Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort. J Immunother Cancer. 2020;8(2):e001076. doi:10.1136/jitc-2020-001076
   PubMed Web of Science ®Google Scholar
• Bhatia S, Nghiem P, Veeranki SP, et al. Real-world clinical outcomes with avelumab in patients with Merkel cell carcinoma treated in the USA: a multicenter chart review study. J Immunother Cancer. 2022;10(8):e004904. doi:10.1136/jitc-2022-004904
   PubMed Web of Science ®Google Scholar
• Walker JW, Lebbé C, Grignani G, et al. Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program. J Immunother Cancer. 2020;8(1):e000313. doi:10.1136/jitc-2019-000313
   PubMed Web of Science ®Google Scholar
• Lewis DJ, Fathy RA, Nugent S, et al. Sentinel lymph node biopsy in Merkel cell carcinoma: rates and predictors of compliance with the National Comprehensive Cancer Network guidelines. J Am Acad Dermatol. 2023;88(2):448–450. doi:10.1016/j.jaad.2022.05.054
   PubMed Web of Science ®Google Scholar
• D’Angelo SP, Lebbé C, Mortier L, et al. First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study. J Immunother Cancer. 2021;9(7):e002646. doi:10.1136/jitc-2021-002646
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Russell JS, Hamid O, et al. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a Phase 2 clinical trial. J Immunother Cancer. 2018;6(1):7. doi:10.1186/s40425-017-0310-x
   PubMed Web of Science ®Google Scholar
• Kamińska-Winciorek G, Cybulska-Stopa B, Lugowska I, Ziobro M, Rutkowski P. Principles of prophylactic and therapeutic management of skin toxicity during treatment with checkpoint inhibitors. Postepy Dermatol Alergol. 2019;36(4):382–391. doi:10.5114/ada.2018.80272
   PubMed Web of Science ®Google Scholar
• Hanania HL, Lewis DJ. Systematic review of programmed cell death-1 inhibitor therapy for advanced-stage cutaneous squamous cell carcinoma in solid-organ transplant recipients. J Dermatolog Treat. 2022;33(8):3119–3126. doi:10.1080/09546634.2022.2118516
   PubMed Web of Science ®Google Scholar
• Pirker R, Fink A, Stella A, Stifter L, Posch C. Hyperprogression of Merkel cell carcinoma after avelumab treatment. J Eur Acad Dermatol Venereol. 2023;37(5):e675–e677. doi:10.1111/jdv.18887
   PubMed Web of Science ®Google Scholar
• Bilić H, Sitaš B, Hančević M, Habek M, Simetić L, Bilić E. Severe demyelinating polyneuropathy and cranial neuropathy during avelumab treatment of metastatic Merkel cell carcinoma. Clin Neuropharmacol. 2021;44(5):193–195. doi:10.1097/WNF.0000000000000464
   PubMed Web of Science ®Google Scholar
• Nghiem P, Bhatia S, Lipson EJ, et al. Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. J Immunother Cancer. 2021;9(4):e002478. doi:10.1136/jitc-2021-002478
   PubMed Web of Science ®Google Scholar
• Glutsch V, Schummer P, Kneitz H, et al. Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG. J Immunother Cancer. 2022;10(11):e005930. doi:10.1136/jitc-2022-005930
   PubMed Web of Science ®Google Scholar
• Al-Showbaki L, Nadler MB, Desnoyers A, Almugbel FA, Cescon DW, Amir E. Network meta-analysis comparing efficacy, safety and tolerability of anti-PD-1/PD-L1 antibodies in solid cancers. J Cancer. 2021;12(14):4372–4378. doi:10.7150/jca.57413
   PubMed Web of Science ®Google Scholar